UNSPSC 51172419: Amylase/dehydrocholic acid/desoxycholic acid/protease

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA500. This VA Drug Class (GA500) classifies this compound as belonging to the group DIGESTANTS.

UNSPSC 51172419 Amylase/dehydrocholic acid/desoxycholic acid/protease (Commodity) covers enzymatic and chemical additives used in diagnostic testing and pharmaceutical applications procured by state and local health agencies, criminal justice departments, and multistate cooperative purchasing consortia. Recent solicitations reveal that state and local buyers under this code are seeking drug-testing reagents, pharmaceutical ingredients for generic formulations, and specialty chemicals supporting specimen analysis and pharmacy benefit programs. Issuing bodies include county criminal justice supervision departments, state health and human services commissions managing pharmacy benefit programs, and multistate cooperative purchasing alliances serving state and local government facilities across multiple jurisdictions.

Activity under this code clusters in Texas and Minnesota. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026 for offender specimen collection and drug testing services, with proposals due July 23, 2026, seeking immunoassay screening with LC/MS/MS or GC/MS confirmation for approximately 25,031 annual tests at an estimated contract value of $600,000 over two years with optional three-year renewals; Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 as a preliminary market-intelligence gathering phase preceding a formal solicitation for direct-to-manufacturer prescription programs. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP (Minnesota Multistate Cooperative Purchasing Alliance), issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and contract awards effective July 1, 2026, requiring products manufactured to cGMP and DSCSA compliance standards with pricing weighted 75 percent in the evaluation.